MAPT and Alzheimer disease: Even with the mounting evidence implicating tau toxicity in AD pathogenesis, data from the AlzForum Foundation (www.alzforum.org) suggest that tau-targeting strategies constitute only 10% of the ongoing clinical trials for AD.